Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events. Rituximab, omalizumab, and dupilumab should be explored as alternative treatment options to improve outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Peng, Xu, Wenjing, Zhang, Litao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235912/
https://www.ncbi.nlm.nih.gov/pubmed/35769474
http://dx.doi.org/10.3389/fimmu.2022.928621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235912/
https://www.ncbi.nlm.nih.gov/pubmed/35769474
http://dx.doi.org/10.3389/fimmu.2022.928621

Ejemplares similares